A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Cornelissen, Lisette A H M ^a   de Vries, Robert P ^b   de Boer Luijtze, Els A ^a   Rigter, Alan ^b   Rottier, Peter J M ^b   de Haan, Cornelis A M ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT PROTEIN; INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LIGAND BINDING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE DRUG DOSE; VIRUS DETECTION; VIRUS SHEDDING; ANIMAL; CHEMISTRY; CHICKEN; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; PROTEIN MULTIMERIZATION; SOLUBILITY; VACCINATION; VIROLOGY;

ANIMALIA; AVES; AVIAN INFLUENZA VIRUS; GALLUS GALLUS; MAMMALIA; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIGENS, VIRAL; CHICKENS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; MICE; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; SOLUBILITY; VACCINATION;

EID: 77956291661     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010645     Document Type: Article

References (30)

1. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152-179.
2. Munster VJ, Fouchier RA (2009) Avian influenza virus: of virus and bird ecology. Vaccine 27: 6340-6344.
3. Uyeki TM (2008) Global epidemiology of human infections with highly pathogenic avian influenza A (H5N1) viruses. Respirology 13 Suppl 1: S2-9.
4. Yen HL, Webster RG (2009) Pandemic influenza as a current threat. Curr Top Microbiol Immunol 333: 3-24.
5. Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27 Suppl 4:D65-68.
6. Safdar A, Cox MM (2007) Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs 16: 927-934.
7. Keitel WA, Atmar RL (2009) Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol 333: 431-451.
8. Mueller SN, Langley WA, Carnero E, Garcia-Sastre A, Ahmed R (2010) Immunization with live-attenuated influenza viruses expressing altered NS1 proteins results in potent and protective memory CD8+T cells responses. J Virol 84: 1847-1855.
9. Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, et al. (2007) Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195: 1598-1606.
10. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirusbased immunization. J Virol 80: 1959-1964.
11. Wu Q, Fang L, Wu X, Li B, Luo R, et al. (2009) A pseudotype baculovirusmediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol Immunol 46: 2210-2217.
12. Dinapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, et al. (2010) Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. pp 1489-1503.
13. Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, et al. (2008) Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 3: e2432.
14. van Oirschot JT (2001) Present and future of veterinary viral vaccinology: a review. Vet Q 23: 100-108.
15. Biesova Z, Miller MA, Schneerson R, Shiloach J, Green KY, et al. (2009) reparation, characterization, and immunogenicity in mice of a recombinant nfluenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/ 004 influenza virus. Vaccine 27: 6234-6238.
16. Wei CJ, Xu L, Kong WP, Shi W, Canis K, et al. (2008) Comparative efficacy of eutralizing antibodies elicited by recombinant hemagglutinin proteins from vian H5N1 influenza virus. J Virol 82: 6200-6208.
17. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, et al. (1999) aculovirus-derived hemagglutinin vaccines protect against lethal influenza nfections by avian H5 and H7 subtypes. Vaccine 17: 2265-2274.
18. Bhattacharya P, Grimme S, Ganesh B, Gopisetty A, Sheng JR, et al. (2010) anodisc-incorporated hemagglutinin provides protective immunity against nfluenza virus infection. J Virol 84: 361-371.
19. Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, et al. (2009) Glycans on nfluenza hemagglutinin affect receptor binding and immune response. Proc atl Acad Sci U S A 106: 18137-18142.
20. Zeng Q, Langereis MA, van Vliet AL, Huizinga EG, de Groot RJ (2008) Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 105: 9065-9069.
21. Harbury PB, Zhang T, Kim PS, Alber T (1993) A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401-1407.
22. Reeves PJ, Hwa J, Khorana HG (1999) Structure and function in rhodopsin: kinetic studies of retinal binding to purified opsin mutants in defined phospholipid-detergent mixtures serve as probes of the retinal binding pocket. Proc Natl Acad Sci U S A 96: 1927-1931.
23. Terpe K (2003) Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 60: 523-533.
24. Zwicker N, Adelhelm K, Thiericke R, Grabley S, Hanel F (1999) Strep-tag II for one-step affinity purification of active bHLHzip domain of human c-Myc. Biotechniques 27: 368-375.
25. Tchoudakova A, Hensel F, Murillo A, Eng B, Foley M, et al. (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs 1:163-171.
26. Durocher Y, Butler M (2009) Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 20: 700-707.
27. Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32: 155-172.
28. Beck I, Gerlach H, Burkhardt E, Kaleta EF (2003) Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3. Vaccine 21: 1006-1022.
29. Herfst S, de Graaf M, Schrauwen EJ, Ulbrandt ND, Barnes AS, et al. (2007) Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 88: 2702-2709.
30. Leenaars PP, Hendriksen CF, Angulo AF, Koedam MA, Claassen E (1994) Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits. Vet Immunol Immunopathol 40: 225-241.